New vaccine shows promise in battling recurrent brain tumors
NCT ID NCT04116658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine called EO2401 in 100 adults with glioblastoma that had come back after standard treatment. The vaccine was given alone or with other drugs to see if it was safe and could help the immune system fight the cancer. The goal was to find better ways to control this aggressive brain tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Georges François Leclerc
Dijon, 21000, France
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hôpital Pitié-Salpétrière
Paris, 75013, France
-
Institit Catala D'Oncologia - Hospital Duran i Reynals
L'Hospitalet de Llobregat, 8908, Spain
-
Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn
Bonn, 53105, Germany
-
Medizinische Fakultät Mannheim der Universität Heidelberg
Mannheim, 68167, Germany
-
Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie
Frankfurt am Main, 60528, Germany
-
Zentrum für Neuroonkologie Universitätsklinikum Tübingen
Tübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.